The Dawn of a New Era: Ready-to-Use Stem Cell Therapies in Veterinary Medicine

A New Chapter for Regenerative Medicine in Practice

In this article for PetVet Magazine, Dr. Linda Black, CEO of Gallant and a longtime leader in veterinary regenerative medicine, outlines how off-the-shelf stem cell therapies are poised to transform the delivery of care for immune-mediated and inflammatory diseases in companion animals.

For years, veterinary stem cell therapy was limited by the logistics of autologous treatment—requiring surgical tissue collection, external processing, and delayed administration. Today, a new class of therapies derived from healthy donor animals enables streamlined, clinic-ready treatment that can be delivered the same day, without complex procedures or specialized equipment.

What Makes Ready-to-Use Stem Cell Therapies Different?

Dr. Black explains how these new therapies are developed from uterine-derived mesenchymal stem cells, also called mesenchymal stromal cells (MSCs), collected during routine spay procedures. The cells are processed under FDA-aligned protocols to ensure purity, potency, and consistency, then frozen for on-demand use. When needed, a vial can be thawed and administered intravenously—enabling any practice, regardless of size or specialization, to offer regenerative care in a practical, scalable way.

Unlike conventional medications that primarily target symptoms, MSCs home to sites of inflammation and immune imbalance, releasing signaling molecules that help modulate immune response and support tissue healing.

Clinical Applications and Systemic Impact

The article highlights several disease states where MSC therapy may offer new value, including feline chronic gingivostomatitis (FCGS), osteoarthritis (OA), chronic kidney disease (CKD), and atopic dermatitis. Because these diseases often involve systemic inflammation—not just localized pathology—Dr. Black emphasizes the advantage of therapies that can address the broader immunological dysfunction at play.

Intravenous administration allows MSCs to reach multiple affected tissues and may offer sustained improvements in clinical signs, quality of life, and treatment burden.

Preparing for the Future of Care

With the first investigational MSC therapy for FCGS moving toward FDA conditional approval, Dr. Black encourages veterinary teams to become informed and ready. From staff education to client-facing communication, practices that embrace regenerative modalities today may be best positioned to meet rising demand for biologic and disease-modifying treatments in the near future.

She also notes that client interest is already high—as seen in ongoing clinical trial participation—and that veterinary teams will play a central role in guiding appropriate use.

Why It Matters

Stem cell therapies may help shift treatment strategies from symptom suppression to immune recalibration and functional tissue restoration. As off-the-shelf delivery makes this class of therapy more widely accessible, regenerative medicine may offer a new pathway for improving outcomes in cases where long-term medications, repeated visits, and disease progression continue to take a toll on patients and their families.

Read the Full Article

Read the full article in PetVet Magazine.

This content is for educational purposes only. The therapy discussed is investigational and not yet commercially available.